Deals this week: TCR2 Therapeutics, DBV Technologies, Novartis

23rd March 2018 (Last Updated March 23rd, 2018 00:00)

US-based immuno-oncology company TCR2 Therapeutics Inc has completed a series B venture financing round co-led by 6 Dimensions Capital and Curative Ventures. 

US-based immuno-oncology company TCR2 Therapeutics Inc has completed a series B venture financing round co-led by 6 Dimensions Capital and Curative Ventures.

The company has raised $125m from the round, which also saw participation of new as well as existing investors.

The proceeds are intended to be used for advancing two TRuC-T cell programs through human proof-of-concept.

DBV Technologies SA has announced the pricing for its planned private placement of ordinary shares.

The company will place 2,135,737 shares priced at €34.71 ($42.68) a share as part of the placement to raise €74.13m ($91.16m) in gross proceeds.

Underwriters have been granted a 30-day option to purchase up to an additional 529,162 ordinary shares.

Proceeds are intended to be used to fund the development and commercialisation of Viaskin Peanut and advance development of other product candidates.

Part of proceeds will also be used for working capital and general corporate purposes.

"The offering includes 8.5 million shares priced at $41.50 a share to raise $352.8m in gross proceeds."

Based in France, DBV Technologies is a biopharmaceutical company.

US-based biopharmaceutical company Arena Pharmaceuticals Inc has announced the pricing for its underwritten public offering of common stock shares.

The offering includes 8.5 million shares priced at $41.50 a share to raise $352.8m in gross proceeds.

Underwriters have been granted a 30-day option to purchase up to 1.275 million additional shares at the same price, less underwriter discounts, and commissions.

Proceeds are intended to be used for clinical and pre-clinical development of the company’s drug candidates, and for general corporate purposes.

Xencor Inc has announced the pricing for its proposed underwritten public offering of shares to raise $226.3m in gross proceeds to fund working capital and general corporate purposes.

Priced at $31 a share, the offering includes 7.3 million shares, while underwriters have been granted an option to purchase up to an additional 1.095 million shares to cover over-allotments.

Based in the US, Xencor Inc is a clinical-stage biopharmaceutical company.